Year: 2026

Alaris Provides Clarifying Amendments to Unitholder Meeting Matters

Written by Customer Service on April 30, 2026. Posted in Public Companies.

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW CALGARY, Alberta, April 30, 2026 (GLOBE NEWSWIRE) — (all numbers in this release are in Canadian dollars (CAN$) unless otherwise noted) Alaris Equity Partners Income Trust (TSX:AD.UN) (“Alaris” or the “Trust”) announced today that based on a further review of its equity compensation plans, it has decided to amend such plans in advance of the Trust’s upcoming annual general and special unitholder meeting scheduled to be held on Thursday, May 7, 2026 (the “Meeting”). In the information circular dated March 18, 2026 (the “Circular”), sent to unitholders of Alaris in connection with the Meeting, the Trust proposed to put to such Unitholders resolutions...

FLUENT Reports Fourth Quarter and Full Year 2025 Results

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

Reduced Long Term Indebtedness Through Partial Prepayment Strengthened Product Portfolio and Wholesale Growth TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the fourth quarter and full year ended December 31, 2025. Unless otherwise indicated, all financial results are presented in U.S. dollars. Management Commentary “Our fourth quarter reflected continued progress on our strategic priorities, with a strong focus on cost optimization and simplifying our operations. In Florida, our Rosa cultivation facility delivered increased output and improved quality, helping to rebalance production across our cultivation footprint. We anticipate...

Societe Generale: First quarter 2026 earnings

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

RESULTS AT 31 MARCH 2026Press release Paris, 30 April 2026 at 6:25 a.m. ROTE OF 11.7%1 IN Q1 26, WELL ABOVE THE 2026 TARGET COST-TO-INCOME RATIO OF 60.9%2 IN Q1 26 COSTS DOWN -6.0% VS. Q1 25 COST OF RISK OF 25BPS, AT THE LOW END OF THE 2026 GUIDANCE RANGERevenues of EUR 7.1 billon in Q1 26, up by +0.3% vs. Q1 25 Strict cost discipline with operating expenses down -6.0% vs. Q1 25, better than the 2026 annual target of a decrease of ~-3% Cost-to-income ratio of 60.9%2 in Q1 26 vs. 65.0% in Q1 25 Cost of risk at 25bps in Q1 26, at the low end of the 2026 guidance range of 25 to 30bps. High S1/S2 buffer of EUR 2.9bn (or ~2.0x 2025 cost of risk) Group net income of EUR 1,696 million in Q1 26, +5.5% vs. Q1 25 Profitability (ROTE) of 11.7% and 12.7% with IFRIC 21 linearisation and excluding...

YXT.com Filed 2025 Annual Report on Form 20-F

Written by Customer Service on April 30, 2026. Posted in Public Companies.

SUZHOU, China, April 29, 2026 (GLOBE NEWSWIRE) — YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 29, 2026 Eastern Time. The annual report can be accessed on the Company’s investor relations website at https://ir.yxt.com. About YXT.com YXT.com (NASDAQ: YXT) is a technology company focusing on enterprise productivity solutions. With a mission to “Empower people and organization development through technology,” the Company strives to become the supreme provider in building and boosting enterprise productivity by combining over a decade of experience in tech-enabled talent learning...

California Water Service Group Reports First Quarter 2026 Financial Results & Provides Update on 2024 California General Rate Case

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) — California Water Service Group (Group or Company, NYSE: CWT), a leading publicly traded water utility serving California, Hawaii, New Mexico, Washington, and Texas, today reported first quarter 2026 results and provided an update on the revised proposed decision issued by the California Public Utilities Commission (CPUC) on April 29, 2026 (revised PD) on California Water Service Company’s (Cal Water’s) 2024 California General Rate Case (2024 CA GRC). First Quarter 2026 in Line with Expectations Given Pending Decision on 2024 CA GRC The Company reported that first-quarter 2026 results were in line with expectations as the Company awaits a final decision on the 2024 CA GRC, which is expected on April 30, 2026, or shortly thereafter. Once a final decision is adopted, the Company has...

Omni Bridgeway Releases 3Q26 Portfolio Update with Exceptionally Strong Investment Pipeline

Written by Customer Service on April 30, 2026. Posted in Public Companies.

SYDNEY, April 29, 2026 (GLOBE NEWSWIRE) — Omni Bridgeway Limited (ASX: OBL), a leading global alternative asset manager specialising in legal assets, has released its Investment Portfolio Report as at 31 March 2026, highlighting a notably increased investment pipeline, continued positive completion metrics, and ongoing strength, scale and diversification of its global legal assets portfolio. Key HighlightsExceptionally Strong Investment Pipeline: Omni Bridgeway contracted 27 new investments FYTD, representing A$391.8 million in new commitments. This is supported by a pipeline of agreed exclusive term sheets representing over A$600 million in further commitments, if contracted — more than 2x the average quarterly pipeline value. This reflects favourable market and competitive dynamics, and an expanding opportunity set into 4Q26...

Avalyn Announces Pricing of Upsized Initial Public Offering

Written by Customer Service on April 30, 2026. Posted in Public Companies.

BOSTON, April 29, 2026 (GLOBE NEWSWIRE) — Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Avalyn from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $300 million. All of the shares are being offered by Avalyn. In addition, Avalyn has granted the underwriters a 30-day option to buy an additional 2,500,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading...

Precision Drilling Announces 2026 First Quarter Unaudited Financial Statements

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, April 29, 2026 (GLOBE NEWSWIRE) — This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, (gain) loss on investments and other assets, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Net Capital Spending, Working Capital and Total Long-Term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial...

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. “We’ve had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year’s launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has successfully achieved its patient recruitment target, and we have bolstered our long-term leadership in the field by acquiring genetically modified technology...

PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results

Written by Customer Service on April 30, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter 2025 revenue up 75% compared to the fourth quarter 2024 Fourth quarter 2025 gross profit increased 78% compared to the fourth quarter 2025 Fourth quarter same-store sales up 6% and same-store prescription sales up 3.8 %, supplementary financial measures, both compared to fourth quarter 2025SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, today reported its financial results for fourth quarter and year ended December 31, 2025. “Our financial results reflect our steady progress in scaling the business through disciplined M&A, the successful integration of recently acquired stores, and the operational excellence of our pharmacies,”...

Year: 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals